Obesity, but not polycystic ovary syndrome, affects circulating markers of low-grade inflammation in young women without major cardiovascular risk factors.

Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder amongst women of reproductive age. Although PCOS is diagnosed exclusively based on reproductive criteria, it is also a metabolic disorder. Insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, obesity, and dyslipidemia are more common in women with PCOS than in age-comparable women without PCOS. Many of t...

Pmn-15: The Role of Lifestyle Modification in Management of Overweight Infertile Women with Polycystic Ovary Syndrome

Background: Polycystic ovary syndrome (PCOS) is a complex, heterogeneous disorder of uncertain etiology, with a prevalence of up to 10% and frequently associated with obesity, with at least 50% of women with polycystic ovary syndrome demonstrating overweight or obesity defined by body mass index >25 or >30 kg/m2. The syndrome is associated with numerous morbidities, including infertility, obste...

Effect of aerobic training in women with polycystic ovary syndrome

Introduction: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder amongst women of reproductive age and is associated with various metabolic perturbations. Chronic low grade inflammation has been reported to participate in the pathogenesis of metabolic syndrome. In this study we examined the effects of 8 weeks aerobic training on serum C-reactive protein level and cardiometab...

Cigarette Smoking and Cardiovascular Risk in Young Women with Polycystic Ovary Syndrome

P-51: The Role of Metformin in Reduction SerumC-Reactive Protein Levels in Women withPolycystic Ovary Syndrome

Background: Low-grade chronic inflammation, reflected in elevated levels of serum C-reactive protein (CRP), has recently been linked to obesity, insulin resistance syndromes such as polycystic ovary syndrome (PCOS), and an increased risk of cardiovascular disease. Because the insulin sensitizer metformin has been shown to improve metabolic disturbances in PCOS, it was of particular interest to ...